| 05/11 | BELLUS : Q1 Earnings Snapshot | AQ |
| 05/11 | Bellus Health Reports Q1 Net Loss of US$14.4 Million, Provides Update | MT |
| 05/11 | BELLUS Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/11 | Earnings Flash (BLU.TO) BELLUS HEALTH Says Ended Q1 2022 with US$234.0 million in cash,.. | MT |
| 05/11 | Earnings Flash (BLU.TO) BELLUS HEALTH Posts Q1 Basic and Diluted Loss US$0.13 | MT |
| 05/11 | BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights | BU |
| 05/11 | TRANSCRIPT : BELLUS Health Inc. - Shareholder/Analyst Call | CI |
| 05/02 | BELLUS HEALTH : to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of B.. | PU |
| 05/02 | BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of .. | BU |
| 05/02 | BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of .. | CI |
| 04/25 | BELLUS HEALTH : to Participate in Multiple Upcoming Investor Conferences - Form 6-K | PU |
| 04/25 | BELLUS Health to Participate in Multiple Upcoming Investor Conferences | BU |
| 04/07 | BELLUS HEALTH : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS - Form 6-K | PU |
| 04/06 | BELLUS HEALTH : Form of Proxy – Annual General Meeting | PU |
| 04/05 | BELLUS HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS - Form 6-K | PU |
| 04/01 | RBC Capital on Bellus Health's BLU-5937'S Path Forward | MT |
| 04/01 | BELLUS HEALTH : Corporate Presentation – April 2022 | PU |
| 03/18 | RBC Capital Keeps Outperform/Speculative, US$14 TP on Bellus, Says Physician Surveys Su.. | MT |
| 03/08 | TRANSCRIPT : BELLUS Health Inc. Presents at 42nd Annual Cowen Health Care Conference, Mar-.. | CI |
| 03/04 | BELLUS HEALTH : Notice of the Meeting and Record Date - Form 6-K | PU |
| 03/01 | BELLUS HEALTH : Corporate Presentation – March 2022 | PU |
| 03/01 | RBC Capital Markets Maintains BELLUS Health's Rating, Price Target | MT |
| 03/01 | BELLUS HEALTH : to Participate in the Cowen & Co. 42nd Annual Health Care Conference - For.. | PU |
| 03/01 | BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference | BU |
| 02/24 | RBC Capital Reiterates Outperform/Speculative Risk, US$14 TP on Bellus Health | MT |
| 02/24 | HC Wainwright Adjusts BELLUS Health's Price Target to $16 From $14, Reiterates Buy Rati.. | MT |
| 02/23 | BELLUS : Q4 Earnings Snapshot | AQ |
| 02/23 | BELLUS HEALTH : Annual Report by Canadian Issuer (Form 40-F) | PU |
| 02/23 | BELLUS Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 02/23 | Bellus Health Reports FY 2021 Net Loss of US$0.90 Per Share | MT |
| 02/23 | BELLUS HEALTH : Reports Year 2021 Financial Results and Business Highlights - Form 6-K | PU |
| 02/23 | BELLUS HEALTH BRIEF : Ended year with US$248.8 million in cash, cash equivalents and short.. | MT |
| 02/23 | BELLUS HEALTH BRIEF : Comes As Announced "Positive" topline results from Phase 2b SOOTHE c.. | MT |
| 02/23 | BELLUS HEALTH BRIEF : Says Plans to request an End-of-Phase 2 meeting with Food and Drug A.. | MT |
| 02/23 | BELLUS Health Reports Year 2021 Financial Results and Business Highlights | BU |
| 02/23 | NORTH AMERICAN MORNING BRIEFING : Stocks to -2- | DJ |
| 02/11 | BELLUS HEALTH : Corporate Presentation – February 2022 | PU |
| 02/04 | RBC Capital Keeps Outperform/Speculative Risk, US$14 TP on Bellus Health | MT |
| 01/24 | U.S. FDA declines to approve Merck's cough drug | RE |
| 01/11 | RBC Capital Keeps Outperform/Speculative Risk Rating, US$14 TP on Bellus Health | MT |
| 2021 | BELLUS HEALTH : Corporate Presentation – December 2021 | PU |
| 2021 | BELLUS HEALTH INC.(NASDAQGS : BLU) added to NASDAQ Biotechnology Index | CI |
| 2021 | BELLUS HEALTH : Closes US$200 Million Public Offering of Common Shares in Canada and the U.. | PU |
| 2021 | BELLUS Health Closes US$200 Million Offering | MT |
| 2021 | BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the .. | BU |
| 2021 | RBC Capital Markets Raises BELLUS Health's Price Target, Reiterates Rating | MT |
| 2021 | RBC Lifts Price Target on BELLUS Health to $14 From $11, Citing 'Strengthening Clinical.. | MT |
| 2021 | BELLUS HEALTH : Announces Pricing of US$200 Million Public Offering in Canada and the Unit.. | PU |
| 2021 | BELLUS Health Prices US$200 Million Public Offering in Canada and the United States | MT |
| 2021 | BELLUS HEALTH BRIEF : Up 0.2% In US Pre-Market After Overnight Pricing US$200 Million Publ.. | MT |
| 2021 | BELLUS Health Prices Public Offering in Canada, US at $8/Share, Expects $200 Million Gr.. | MT |
| 2021 | BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the Uni.. | BU |
| 2021 | CORRECTION : Top Midday Gainers | MT |
| 2021 | BELLUS Health Launches Public Offering of Common Shares in Canada and the U.S.; Shares .. | MT |
| 2021 | BELLUS Health Launches Common Stock Offering in Canada, US | MT |
| 2021 | BELLUS HEALTH : Announces the Launch of a Public Offering of Common Shares in Canada and t.. | PU |
| 2021 | BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and .. | BU |
| 2021 | Health Care Stocks Finishing Near Intra-Day Highs | MT |
| 2021 | SECTOR UPDATE : Health Care | MT |
| 2021 | Top Midday Decliners | MT |
| 2021 | Evercore ISI Adjusts Price Target on BELLUS Health to $20 From $12, Maintains Outperfor.. | MT |
| 2021 | BTIG Research Adjusts BELLUS Health PT to $18 From $13, Maintains Buy Rating | MT |
| 2021 | BELLUS Health up 62% on TSX to 18-Month High on "Positive" Topline Results From Phase 2.. | MT |
| 2021 | IIROC Trade Resumption - BLU | AQ |
| 2021 | IIROC Trading Halt - BLU | AQ |
| 2021 | Wall Street Set for Positive Open, S&P 500 Futures Poised to Add to Friday's Record Clo.. | MT |
| 2021 | BELLUS Health up 43% to Fresh Year High in US Pre-Market on "Positive" Topline Results .. | MT |
| 2021 | BELLUS Health up 36% to 52-Week High in US Pre-Market on "Positive" Topline Results Fro.. | MT |
| 2021 | Top Premarket Gainers | MT |
| 2021 | TRANSCRIPT : BELLUS Health Inc. - Special Call | CI |
| 2021 | BELLUS Health Details "Positive" Topline Results From Phase 2b SOOTHE Trial For Treatm.. | MT |
| 2021 | BELLUS HEALTH BRIEF : Details "Positive" Topline Results from its Phase 2b SOOTHE Trial of.. | MT |
| 2021 | BELLUS HEALTH : Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5.. | PU |
| 2021 | BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-.. | BU |
| 2021 | Bellus Health Announces Positive Topline Results from Its Phase 2B Soothe Trial of Blu-.. | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
